Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial)

Publication | Closed Access

Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the bezafibrate infarction prevention trial)

DOI

157

Citations

References

1993

Year

Uri Goldbourt, Solomon Behar, Henrietta Reicher-Reiss, Jacob Agmon, Elieser Kaplinsky, E. Graft, Yehezkiel Kishon, Avraham Caspi, Joshua Weisbort, Lori Mandelzweig,

The American Journal of Cardiology

Metabolic SyndromeSecondary Prevention TrialCardiovascular DiseaseHealth PolicyDyslipidemiaPublic HealthMedicineAtherosclerosisEpidemiologyCoronary Artery DiseaseCoronary Heart Disease